会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明公开
    • 바실러스 속 균주 유래의 폴리 감마 글루탐산합성유전자를 이용한 펩타이드 항생물질 P5와Anal3의 표면 발현 방법 및 그의 용도
    • 使用PGS BCA基因的表达P5和ANAL3表达的方法
    • KR1020040034780A
    • 2004-04-29
    • KR1020020063379
    • 2002-10-17
    • 한국생명공학연구원주식회사 바이오리더스학교법인조선대학교
    • 성문희홍승표이종수정창민함경수이동건박윤경김철중부하령
    • C12N15/63
    • C12N15/70A61K35/747C12N15/746C12Y603/02
    • PURPOSE: A method for surface expression of peptides P5 and Anal3 using pgs BCA gene is provided, thereby removing a purification process of peptides P5 and Anal3, and using useful lactic acid bacteria for the surface expression, so that peptide antibiotics can be cheaply and stably mass-produced. CONSTITUTION: A surface expression vector of antibiotics pHCE1LB:pgsA-P5 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide P5 encoded by the nucleotide sequence set forth in SEQ ID NO: 4. Transformed microorganisms with the vector pHCE1LB:pgsA-P5, Escherichia coli(KCTC 10350BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide P5 is surface expressed, or peptide P5 contained Lactobacillus floating matters as effective components. A surface expression vector of antibiotics pHCE1LB:pgsA-Anal3 comprises one or more genes encoding polygammaglutamic acid synthase complex selected from pgsB, pgsC and pgsA, and a gene dipolar peptide antibiotics having antimicrobial, antifungal and anticancer activities, wherein the dipolar peptide antibiotics has homology to the peptide Anal3 encoded by the nucleotide sequence set forth in SEQ ID NO: 6. Transformed microorganisms with the vector pHCE1LB:pgsA-Anal3, Escherichia coli(KCTC 10348BP) or Lactobacillus casei are provided. A pharmaceutical composition for antimicrobial, antifungal or anticancer comprises Lactobacillus casei on which the peptide Anal3 is surface expressed, or peptide Anal3 contained Lactobacillus floating matters as effective components.
    • 目的:提供使用pgs BCA基因表达肽P5和Anal3的方法,从而消除肽P5和Anal3的纯化过程,并使用有用的乳酸菌进行表面表达,使肽抗生素可以廉价稳定 大规模生产的。 构成:抗生素pHCE1LB:pgsA-P5的表面表达载体包含一种或多种编码选自pgsB,pgsC和pgsA的聚氨基丁酸合酶复合物的基因,以及具有抗微生物,抗真菌和抗癌活性的基因偶极肽抗生素,其中偶极肽抗生素 与由SEQ ID NO:4所示的核苷酸序列编码的肽P5具有同源性。提供了具有载体pHCE1LB:pgsA-P5,大肠杆菌(KCTC 10350BP)或干酪乳杆菌的转化微生物。 用于抗微生物,抗真菌或抗癌的药物组合物包括其上表达肽P5的干酪乳杆菌,或肽P5含有乳杆菌漂浮物作为有效成分。 抗生素pHCE1LB:pgsA-Anal3的表面表达载体包含一个或多个编码选自pgsB,pgsC和pgsA的聚氨基丁酸合酶复合物的基因,以及具有抗微生物,抗真菌和抗癌活性的基因偶极肽抗生素,其中偶极肽抗生素具有同源性 与由SEQ ID NO:6所示的核苷酸序列编码的肽Anal3进行比较。提供了具有载体pHCE1LB:pgsA-Anal3,大肠杆菌(KCTC 10348BP)或干酪乳杆菌的转化微生物。 用于抗微生物,抗真菌或抗癌的药物组合物包括其上表达表达肽Anal3的干酪乳杆菌,或肽Anal3含有乳杆菌漂浮物作为有效成分。
    • 3. 发明公开
    • 바실러스 속 균주 유래의 폴리감마글루탐산 합성유전자를이용한 표면 발현용 벡터 및 이를 이용한 단백질의 미생물표면 발현 방법
    • 包含PGSBCA,编码多糖 - 谷氨酸合成酶的基因的表面表达载体,以及使用其表达微生物表面上的靶标蛋白的方法
    • KR1020040032824A
    • 2004-04-17
    • KR1020037016665
    • 2002-08-09
    • 한국생명공학연구원주식회사 바이오리더스(주)엠디랩
    • 성문희홍승표이종수정창민김철중부하령소다겐지아시우치마코토
    • C12N15/75
    • C12N9/1051C07K2319/02C12N9/1288C12Y204/01133C12Y207/08005
    • PURPOSE: A surface expression vector including pgsBCA, a gene encoding poly-gamma-glutamate synthetase, and a method for expressing a target protein on the surface of a microorganism using the same are provided. The surface expression vector can be effectively used for the stable and easily detachable surface expression of various exogenous proteins onto the cell surface regardless of the cell cycle. CONSTITUTION: Surface expression vectors for producing a protein on a microbial surface contains one or more than two genes selected among pgsB, pgsC and pgsA, encoding a poly-γ-glutamate synthetase complex, wherein the gene is derived from a Bacillus sp. strain producing poly-γ-glutamate synthetase; and the nucleotide sequences of pgsB, pgsC and pgsA genes are homologous to those of SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively, with an 80% homology. A method for expressing a target protein on the surface of a microorganism comprises the steps of: (a) constructing a recombinant expression vector by inserting a gene encoding the target protein into the surface expression vector; (b) transforming a Gram-negative host cell with the recombinant vector; and cultivating the transformed host cell and expressing the target protein on the surface of the host cell.
    • 目的:提供包含pgsBCA,编码聚-γ-谷氨酸合成酶的基因的表面表达载体和使用其的表达微生物的靶蛋白的方法。 无论细胞周期如何,表面表达载体都可以有效地用于将各种外源蛋白质稳定且容易地分离到细胞表面上的表面表达。 构成:用于在微生物表面上产生蛋白质的表面表达载体含有一个或多于两个选自pgsB,pgsC和pgsA的基因,编码聚-γ-谷氨酸合成酶复合物,其中该基因源自芽孢杆菌属。 生产聚-γ-谷氨酸合成酶的菌株; pgsB,pgsC和pgsA基因的核苷酸序列分别与SEQ ID NO:1,SEQ ID NO:2和SEQ ID NO:3的核苷酸序列同源,具有80%的同源性。 用于在微生物表面上表达靶蛋白的方法包括以下步骤:(a)通过将编码靶蛋白的基因插入表面表达载体来构建重组表达载体; (b)用重组载体转化革兰氏阴性宿主细胞; 并培养转化的宿主细胞并在宿主细胞的表面上表达靶蛋白。
    • 6. 发明公开
    • 사스 바이러스 항원의 세포표면 발현벡터 및 상기 벡터에의해 형질전환된 미생물
    • SARS病毒抗原和微生物的细胞表面表达载体转化用于生产疫苗用于预防或治疗SARS
    • KR1020040104936A
    • 2004-12-13
    • KR1020040040894
    • 2004-06-04
    • 주식회사 바이오리더스(주)제노락 BL한국생명공학연구원(주)엠디랩
    • 성문희김철중정창민홍승표이종수최재철김광주니치구로다부하령
    • C12N15/86
    • C07K14/005A61K39/00A61K2039/523C07K2319/00C12N9/93C12N15/74C12N2710/20022C12N2770/20022Y02A50/472Y02A50/476
    • PURPOSE: A cell surface expression vector of SARS virus antigen and a microorganism transformed thereby are provided. The transformed microorganism and antigen protein produced therefrom are useful in the production of a vaccine for the prevention or treatment of SARS. CONSTITUTION: The cell surface expression vector of SARS virus antigen comprises one or more than two genes selected from genes encoding polygammaglutamic acid synthetase complex, pgsB, pgsC and pgsA; and a gene encoding a spike antigen protein of SARS coronavirus or a nucleocapsid antigen protein, wherein the spike antigen protein is SARS SA, SARS SB, SARS SC or SARS SBC; the nucleocapsid antigen is SARS NA, SARS NB or SARS N; and the expression vector is pHCE2LB:pgsA-SARS SA, pHCE2LB:pgsA-SARS SC or pHCE2LB:pgsA-SARS SBC. The transformed microorganism is produced by transforming with the cell surface expression vector of SARS virus antigen, wherein the microorganism is selected from Escherichia coli, Salmonella typhi, Salmonella typhimurium, Vibrio cholera, Mycobacterium bovis, Shigella sp., Bacillus sp., lactic acid bacteria, Staphylococcus sp., Listeria monocytogenes and Streptococcus sp.
    • 目的:提供SARS病毒抗原和由此转化的微生物的细胞表面表达载体。 由此产生的转化的微生物和抗原蛋白质可用于生产用于预防或治疗SARS的疫苗。 构成:SARS病毒抗原的细胞表面表达载体包含选自编码聚氨基丁酸合成酶复合物,pgsB,pgsC和pgsA的基因中的一种或两种以上的基因; 以及编码SARS冠状病毒或核衣壳抗原蛋白的尖峰抗原蛋白的基因,其中尖峰抗原蛋白为SARS SA,SARS SB,SARS SC或SARS SBC; 核衣壳抗原为SARS NA,SARS NB或SARS N; 表达载体为pHCE2LB:pgsA-SARS SA,pHCE2LB:pgsA-SARS SC或pHCE2LB:pgsA-SARS SBC。 通过用SARS病毒抗原的细胞表面表达载体转化产生转化的微生物,其中微生物选自大肠杆菌,伤寒沙门氏菌,鼠伤寒沙门氏菌,霍乱弧菌,牛分枝杆菌,志贺氏杆菌,芽孢杆菌,乳酸菌 ,葡萄球菌属(Staphylococcus sp。),单核细胞增生利斯特氏菌(Listeria monocytogenes)和链球菌属(Streptococcus sp。)。
    • 9. 发明公开
    • 인간 파필로마바이러스에 대한 백신용 벡터 및 그에 의해형질전환된 미생물
    • 用于抗HPV(人造血管病毒)疫苗和转化的微生物的载体
    • KR1020040034511A
    • 2004-04-28
    • KR1020030072407
    • 2003-10-17
    • 주식회사 바이오리더스한국생명공학연구원
    • 성문희부하령이종수정창민홍승표김철중박순희표현미
    • C12N15/86
    • C07K14/005A61K39/0011A61K2039/523C12N7/00C12N2710/20022C12N2730/10122C12N2830/008
    • PURPOSE: A vector for anti-HPV(human Papillomavirus) vaccine and a transformed microorganism therewith are provided, thereby expressing capsid L1 protein of human Papillomavirus on the surface of the microorganism, so that the transformed microorganism can be useful for prevention and treatment of hPV. CONSTITUTION: A vector for anti-HPV(human Papillomavirus) vaccine contains one or two gene selected from pgsB, pgsC and pgsA encoding polygammaglutamic acid synthase complex and an antigen protein gene of human Papillomavirus, wherein the antigen protein gene is one or two surface antigen protein gene selected from HPV capsid L1 and L2 or one or two antigen protein gene selected from HPV E6 and E7. The transformed microorganism with the vector for anti-HPV(human Papillomavirus) vaccine is provided, wherein the microorganism is selected from Escherichia coli, Salmonella typhi, Salmonella typhimurium, Vibrio cholera, Mycobacterium bovis, Shigella, Bacillus, Lactobacillus, Lactococcus, Staphylococcus, Listeria monocytogenes and Streptococcus.
    • 目的:提供用于抗HPV(人乳头瘤病毒)疫苗和转化的微生物的载体,从而在微生物表面上表达人乳头瘤病毒的衣壳L1蛋白,从而转化的微生物可用于预防和治疗hPV 。 构成:用于抗HPV(人乳头瘤病毒)疫苗的载体含有选自编码聚氨基葡萄酸合酶的pgsB,pgsC和pgsA的一个或两个基因和人乳头瘤病毒的抗原蛋白基因,其中抗原蛋白基因是一个或两个表面抗原 选自HPV衣壳L1和L2的蛋白质基因或选自HPV E6和E7的一个或两个抗原蛋白基因。 提供了具有抗HPV(人乳头瘤病毒)疫苗载体的转化微生物,其中微生物选自大肠杆菌,伤寒沙门氏菌,鼠伤寒沙门氏菌,霍乱弧菌,牛分枝杆菌,志贺氏菌,芽孢杆菌,乳杆菌属,乳球菌属,葡萄球菌属,李斯特菌 单核细胞增多和链球菌。